New agreement streamlines Harvard research collaborations with Facebook

Research alliance will advance small-molecule therapy for most common form of acute leukemia, targeting proteins involved in transcriptional regulation.

UCB-funded Harvard study describes the pre-clinical development of a therapeutic that could potentially be used to treat type 2 diabetes, fatty liver disease, and other metabolic diseases.

Biologists at Harvard Medical School, with support from Biogen, have mapped protein networks in the human 'interactome'.